Sera Prognostics, Inc. SERA
Sera Prognostics, Inc. (Nasdaq: SERA) is an endocrine/women's health diagnostics company. Its next catalyst on record is PreTRM test: Multi-state, multi-thousand-patient pilot with commercial insurer (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: PreTRM test — Multi-state, multi-thousand-patient pilot with commercial insurer (2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PreTRM test | Prediction of spontaneous preterm birth risk | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other endocrine/women's health companies
- DexCom, Inc. DXCM
- Utah Medical Products Inc UTMD
- Femasys Inc FEMY
- Pulsenmore Ltd. PLSM
- Trinity Biotech PLC TRIB
- INVO Fertility, Inc. IVF
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.